{"id":612013,"date":"2026-09-05T08:36:31","date_gmt":"2026-09-05T08:36:31","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/612013\/hemophilia-b-market-is-projected-to-witness-significant-growth-by-2036-owing-to-advancements-in-gene-therapy-and-expansion-of-nonfactor-replacement-treatments-delveinsight.html"},"modified":"2026-09-05T08:36:31","modified_gmt":"2026-09-05T08:36:31","slug":"hemophilia-b-market-is-projected-to-witness-significant-growth-by-2036-owing-to-advancements-in-gene-therapy-and-expansion-of-nonfactor-replacement-treatments-delveinsight","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/612013\/hemophilia-b-market-is-projected-to-witness-significant-growth-by-2036-owing-to-advancements-in-gene-therapy-and-expansion-of-nonfactor-replacement-treatments-delveinsight.html","title":{"rendered":"Hemophilia B Market is Projected to Witness Significant Growth by 2036 Owing to Advancements in Gene Therapy and Expansion of Non-Factor Replacement Treatments | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788500400.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hemophilia B Market is Projected to Witness Significant Growth by 2036 Owing to Advancements in Gene Therapy and Expansion of Non-Factor Replacement Treatments | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788500400.jpg\" alt=\"Hemophilia B Market is Projected to Witness Significant Growth by 2036 Owing to Advancements in Gene Therapy and Expansion of Non-Factor Replacement Treatments | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The market dynamics for Hemophilia B are witnessing steady growth driven by advancements in diagnostic capabilities, increasing disease awareness, improved access to specialized care centers, and the growing adoption of prophylactic treatment.<\/div>\n<p style=\"text-align: justify\">(Albany, New York)- 5th Sep 2026, The market dynamics for Hemophilia B are witnessing steady growth driven by advancements in diagnostic capabilities, increasing disease awareness, improved access to specialized care centers, and the growing adoption of prophylactic treatment. Additionally, the development and adoption of gene therapies, extended half-life factor IX therapies, siRNA-based therapies, and non-factor replacement treatments, along with the introduction of QFITLIA (fitusiran), are expected to further propel the Hemophilia B market during the forecast period.<\/p>\n<p style=\"text-align: justify\">DelveInsight, a leading market research firm, announces the release of its latest report, &#8220;DelveInsight&#8217;s Hemophilia B Market Insights, Epidemiology and Market Forecast &ndash; 2036.&#8221; This comprehensive report provides an in-depth understanding of Hemophilia B, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">Key Takeaways from the Hemophilia B Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The market size for Hemophilia B in the leading markets is expected to grow significantly by 2036.<\/p>\n<\/li>\n<li>\n<p>The 7MM Hemophilia B market was valued at approximately USD 3,500 million in 2025 and is projected to reach around USD 4,000 million by 2036, growing at a CAGR of 8.4% during 2026&ndash;2036.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s estimates, the total prevalent cases of Hemophilia B in the 7MM were approximately 11,500 in 2025.<\/p>\n<\/li>\n<li>\n<p>Among EU4 and the UK, France had the highest diagnosed prevalent cases of Hemophilia B, with approximately 1,700 cases in 2025, followed by the UK and Italy, while Spain had the lowest diagnosed prevalent cases.<\/p>\n<\/li>\n<li>\n<p>Among Hemophilia B patients in the United States, approximately 250 cases were inhibitor patients, while approximately 4,500 cases were non-inhibitor patients in 2025.<\/p>\n<\/li>\n<li>\n<p>In 2025, there were approximately 1,600 mild, 1,700 moderate, and 1,100 severe cases of Hemophilia B in the United States.<\/p>\n<\/li>\n<li>\n<p>The United States Hemophilia B market was estimated at approximately USD 2 billion in 2025, with recombinant FIX Extended Half-Life therapies capturing the highest market share.<\/p>\n<\/li>\n<li>\n<p>The most common treatment for Hemophilia B is replacement therapy, with recombinant Factor IX products including BeneFIX, RIXUBIS, IXINITY, ALPROLIX, IDELVION, and REBINYN available in the United States.<\/p>\n<\/li>\n<li>\n<p>HEMGENIX (etranacogene dezaparvovec-drlb) is an FDA-approved gene therapy designed to provide long-term Factor IX expression and represents a potentially durable treatment approach for Hemophilia B.<\/p>\n<\/li>\n<li>\n<p>QFITLIA (fitusiran) was approved by the US FDA in March 2025 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients aged 12 years and older with Hemophilia A or B, with or without inhibitors.<\/p>\n<\/li>\n<li>\n<p>Leading Hemophilia B companies, including Centessa Pharmaceuticals, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Spark Therapeutics, Be Biopharma, Equilibra Bioscience, Regeneron Pharmaceuticals, Intellia Therapeutics, Novo Nordisk, and others, are actively developing innovative therapies expected to transform the Hemophilia B treatment landscape over the coming years.<\/p>\n<\/li>\n<li>\n<p>Promising Hemophilia B therapies in clinical development include BE-101, SR604, REGV131-LNP1265, PF-06741086 (Marstacimab), SerpinPC, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Keen to know more about the market? Request our sample page at<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market<\/a><\/p>\n<p style=\"text-align: justify\">Key Factors Driving the Hemophilia B MarketAdvancements in Hemophilia B Diagnosis<\/p>\n<p style=\"text-align: justify\">Although Hemophilia B is a rare genetic bleeding disorder, improvements in diagnostic capabilities and increasing disease awareness are leading to earlier and more accurate identification of patients. The adoption of advanced coagulation assays, genetic testing, and neonatal screening programs has enhanced detection rates, particularly in developed markets. Improved diagnosis expands the identified patient pool, supports timely initiation of prophylactic therapy, and contributes to overall market growth.<\/p>\n<p style=\"text-align: justify\">Expansion of Gene and Non-Factor Therapies<\/p>\n<p style=\"text-align: justify\">The Hemophilia B treatment landscape is evolving rapidly with the development of gene therapies, non-factor replacement treatments, and extended half-life Factor IX therapies. These approaches aim to provide longer-term disease control, reduce treatment frequency, and address the treatment burden associated with conventional Factor IX replacement.<\/p>\n<p style=\"text-align: justify\">Growing Demand for Reduced Treatment Burden<\/p>\n<p style=\"text-align: justify\">Most conventional Hemophilia B therapies require intravenous administration, which can be inconvenient because of the setup and administration time, pain associated with venous access, and frequent injections. The development of subcutaneous therapies and one-time gene therapy approaches is therefore expected to improve convenience and treatment adherence.<\/p>\n<p style=\"text-align: justify\">Robust Pipeline of Emerging Therapies<\/p>\n<p style=\"text-align: justify\">The Hemophilia B pipeline includes diverse therapeutic approaches such as extended half-life therapies, siRNA, antibodies, cellular therapies, and gene therapies. Emerging candidates such as BE-101, SR604, REGV131-LNP1265, Marstacimab, and SerpinPC are expected to provide additional treatment options and contribute to market growth during the forecast period.<\/p>\n<p style=\"text-align: justify\">Hemophilia B Competitive Landscape<\/p>\n<p style=\"text-align: justify\">The Hemophilia B treatment landscape has historically been dominated by Factor IX replacement therapy, which remains the foundation of treatment for both on-demand and prophylactic management. Available recombinant Factor IX products in the United States include BeneFIX, RIXUBIS, IXINITY, ALPROLIX, IDELVION, and REBINYN. Long-acting extended half-life therapies such as ALPROLIX and IDELVION have improved dosing convenience by reducing infusion frequency, although they still require lifelong intravenous administration.<\/p>\n<p style=\"text-align: justify\">The landscape has expanded with the introduction of HEMGENIX (etranacogene dezaparvovec-drlb), developed by CSL Behring and uniQure. HEMGENIX is an AAV5-based gene therapy that was approved in November 2022 for adults with Hemophilia B who use Factor IX prophylaxis or have a history of life-threatening or repeated serious spontaneous bleeding episodes.<\/p>\n<p style=\"text-align: justify\">The emergence of non-factor replacement therapies is further diversifying the market. QFITLIA (fitusiran), developed by Sanofi, is an antithrombin-lowering therapy administered subcutaneously and was approved in the United States in 2025 for routine prophylaxis. ALHEMO (concizumab) from Novo Nordisk inhibits tissue factor pathway inhibitor and provides another subcutaneous non-factor treatment approach.<\/p>\n<p style=\"text-align: justify\">The emerging pipeline includes novel cellular and gene therapy approaches. BE-101, developed by Be Biopharma, is an engineered B Cell Medicine that uses genetically edited autologous B cells to continuously produce therapeutic levels of Factor IX. SR604, developed by Equilibra Bioscience, is a monoclonal antibody designed to selectively inhibit activated protein C anticoagulant function. Marstacimab and SerpinPC represent additional emerging non-factor approaches being evaluated for Hemophilia B.<\/p>\n<p style=\"text-align: justify\">These emerging therapies are expected to further reshape the Hemophilia B treatment landscape over the forecast period.<\/p>\n<p style=\"text-align: justify\">Discover more about therapies set to grab major Hemophilia B market share @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Hemophilia B Treatment Landscape<\/a><\/p>\n<p style=\"text-align: justify\">Recent Developments in the Hemophilia B Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>In March 2025, Sanofi announced that the US Food and Drug Administration (FDA) approved QFITLIA (fitusiran) as the first antithrombin-lowering therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with Hemophilia A or B, with or without factor VIII or IX inhibitors.<\/p>\n<\/li>\n<li>\n<p>In July 2025, Be Biopharma announced that the first patient was dosed in the first-in-human Phase I\/II BeCoMe-9 clinical trial evaluating BE-101 in adults with moderately severe to severe Hemophilia B in the United States.<\/p>\n<\/li>\n<li>\n<p>In June 2024, the US FDA granted Orphan Drug Designation to BE-101 for the treatment of Hemophilia B.<\/p>\n<\/li>\n<li>\n<p>In December 2025, CSL Behring reported long-term follow-up data for HEMGENIX, demonstrating sustained Factor IX expression and durable bleed control over 4&ndash;5 years, reinforcing its potential as a one-time gene therapy for Hemophilia B.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">What is Hemophilia B?<\/p>\n<p style=\"text-align: justify\">Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by insufficient levels of Factor IX (FIX), a blood-clotting protein required for normal coagulation. The severity of Hemophilia B depends on the amount of Factor IX present in the blood.<\/p>\n<p style=\"text-align: justify\">Patients with Hemophilia B can experience prolonged or spontaneous bleeding, with bleeding episodes potentially affecting joints, muscles, and other parts of the body. Mild and moderate cases may remain undiagnosed during the early stages because initial bleeding episodes may not be very intense.<\/p>\n<p style=\"text-align: justify\">Diagnosis is based on the patient&#8217;s personal and family history of bleeding and specialized laboratory testing. The initial assessment generally includes the activated partial thromboplastin time (aPTT), followed by specific Factor IX assays to confirm the diagnosis and determine disease severity. Genetic testing may also support diagnosis and inheritance assessment.<\/p>\n<p style=\"text-align: justify\">Treatment primarily aims to prevent and control bleeding episodes and improve quality of life. Factor IX replacement therapy remains the foundation of treatment, while extended half-life products, non-factor therapies, and gene therapy are expanding available treatment options. Gene therapy offers the potential for sustained Factor IX expression following a single administration and may reduce the need for ongoing prophylaxis.<\/p>\n<p style=\"text-align: justify\">Hemophilia B Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify\">The Hemophilia B epidemiology section provides insights into the historical and current Hemophilia B patient pool and forecasted trends across the seven major markets. The Hemophilia B market report provides epidemiological analysis for the study period 2022&ndash;2036, segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Diagnosed Prevalent Cases of Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Severity-specific Diagnosed Prevalent Cases of Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Age-specific Diagnosed Prevalent Cases of Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Diagnosed Prevalent Cases of Hemophilia B With or Without Inhibitors<\/p>\n<\/li>\n<li>\n<p>Treated Patient Pool of Hemophilia B<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Scope of the Hemophilia B Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Therapeutic Assessment: Current marketed and emerging therapies for Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, patient burden, and market outlook<\/p>\n<\/li>\n<li>\n<p>Key Companies: Centessa Pharmaceuticals, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Spark Therapeutics, Be Biopharma, Equilibra Bioscience, Regeneron Pharmaceuticals, Intellia Therapeutics, Novo Nordisk, and others<\/p>\n<\/li>\n<li>\n<p>Key Therapies: Fitusiran (QFITLIA), Concizumab (ALHEMO), Etranacogene dezaparvovec (HEMGENIX), SEVENFACT, BE-101, SR604, REGV131-LNP1265, PF-06741086 (Marstacimab), and others<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis<\/p>\n<\/li>\n<li>\n<p>Unmet Needs, KOL&#8217;s Views, Analyst&#8217;s Views, Hemophilia B Market Access and Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">To know more about Hemophilia B companies working in the treatment market, visit @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Hemophilia B Clinical Trials and Therapeutic Assessment<\/a><\/p>\n<p style=\"text-align: justify\">Table of Contents<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Hemophilia B Market Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary for Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Key Events of Hemophilia B<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis of Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Patient Share (%) Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Background and Overview<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Country-Specific Patient Population of Hemophilia B<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Current Treatment and Medical Practices<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Market Outlook<\/p>\n<\/li>\n<li>\n<p>Country-Wise Hemophilia B Market Analysis (2022&ndash;2036)<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Market Drivers<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Market Barriers<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Appendix<\/p>\n<\/li>\n<li>\n<p>Hemophilia B Report Methodology<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">About DelveInsight<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hemophilia-b-market-is-projected-to-witness-significant-growth-by-2036-owing-to-advancements-in-gene-therapy-and-expansion-of-nonfactor-replacement-treatments-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hemophilia-b-market-is-projected-to-witness-significant-growth-by-2036-owing-to-advancements-in-gene-therapy-and-expansion-of-nonfactor-replacement-treatments-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The market dynamics for Hemophilia B are witnessing steady growth driven by advancements in diagnostic capabilities, increasing disease awareness, improved access to specialized care centers, and the growing adoption of<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/612013"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=612013"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/612013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=612013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=612013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=612013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}